Skip to main content
. 2010 Dec 31;16(4):355–361. doi: 10.3350/kjhep.2010.16.4.355

Figure 1.

Figure 1

Cumulative survival curves of the high-dose hepatic arterial infusion chemotherapy (HAIC) group (dashed line) and the conventional transarterial chemoembolization (TACE) group (solid line). Overall survival was significantly longer in the high-dose HAIC group than in the conventional TACE group (median survival, 193 vs. 119 days; log-rank test, P=0.026).